Back to Journals » Lung Cancer: Targets and Therapy » Volume 12
Review
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Immunotherapy for Stage III NSCLC: Durvalumab and Beyond
Total article views | HTML views | PDF downloads | Totals | ||
---|---|---|---|---|---|
9,932 | Dovepress* | 7,281+ | 210 | 7,491 | |
PubMed Central* | 2,651 | 384 | 3,035 | ||
Totals | 9,932 | 594 | 10,526 | ||
*Since 2 November 2021 |
Total mentioned | Delicious | Others | |||
---|---|---|---|---|---|
21 | 0 | 0 | 1 | 8 | 12 |
View citations on PubMed Central and Google Scholar